CytomX Upgrade Follows 32% Response Rate, $894M NPV for Varseta-M
Varseta-M demonstrates 32% response rate at 10 mg/kg Q3W and 20% at 8.6 mg/kg Q3W, with 7.1-month progression-free survival and manageable safety, prompting a speculative Buy upgrade and risk-adjusted NPV of $894M. Q4 loss of $26.5M and $663K revenue missed expectations, underlining reliance on pivotal trial potential in 2027.
1. Clinical Data Drives Upgrade
Varseta-M (CX-2051) showed a 32% objective response at 10 mg/kg Q3W and 20% at 8.6 mg/kg Q3W, with median progression-free survival of 7.1 months and manageable safety under prophylactic measures. These findings supported a speculative Buy rating upgrade.
2. Valuation Hinge on Varseta-M
Analysts modeled a risk-adjusted net present value of $894 million for Varseta-M and pegged a fully diluted fair value of $7.15 per share, underscoring CTMX’s valuation dependence on successful 3L+ mCRC trials. A pivotal trial is anticipated in 2027.
3. Q4 Financial Miss and Outlook
CTMX reported a Q4 loss of $26.5 million (22 cents per share) on $663,000 revenue, missing consensus estimates of an 8 cent loss and $7.4 million revenue. The shortfall highlights near-term cash burn and heightens reliance on upcoming clinical catalysts.